Retina/Vitreous News

In a paper recently published in Retina, an expert panel of retina specialists provided guidance on suprachoroidal space injection.

PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world settings, matching those of phase 3 clinical trials, according to a speaker at Clinical Trials at the Summit.

The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.

PARK CITY, Utah — APX3330, an investigational systemic treatment for diabetic retinopathy, showed encouraging outcomes in the phase 2 ZETA-1 trial, paving the way to phase 3.

Pars plana vitrectomy with internal limiting membrane peeling for macular hole closure is better than pars plana vitrectomy without internal limiting membrane peeling, according to a study.

Patients with epiretinal membrane after proliferative vitreoretinopathy repair may benefit from early peeling, according to a study presented at the American Society of Retina Specialists annual meeting.

In this Healio Video Perspective from the ASRS meeting, Carl C. Awh, MD, FASRS, of Tennessee Retina discusses the phase 3 Pagoda trial investigating the port delivery system with ranibizumab for diabetic macular edema.

Merck has announced the acquisition of all outstanding shares of EyeBio, making it a wholly-owned subsidiary, according to a company press release.

Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients with biallelic RPE65 mutation-associated retinal diseases, according to a study.

In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.